Asia’s biopharma landscape is shifting rapidly toward innovation, with countries such as South Korea, Singapore, India, and Taiwan advancing R&D capabilities. Japan, after a period of slowing innovation, is repositioning biopharma as a strategic priority through regulatory reform, pricing policy changes, increased R&D funding, and startup support. Initiatives spanning regenerative medicine, digital transformation, and AI-driven drug discovery—backed by strong university–industry collaboration and venture funding—are revitalising Japan’s ecosystem and positioning the country to re-emerge as a leading Asian biopharma innovation hub.
